ABL1 BCR::ABL V186A

CI-VAR-00005090Explore in graph →CIViC 2903

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Chronic Myeloid Leukemia, BCR-ABL1 Positive1
ABL1 BCR::ABL V186A	Imatinib	Predictive	C	Supports Resistance	2	rejected	EID7828 One chronic myeloid leukemia patient in chronic phase with the BCR-ABL1 fusion and the V186A secondary variant in 2/12 clones had no response to imatinib before becoming completely resistant. PMID 16775234 · Talpaz et al., 2006 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.